At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antithrombotics; Prostaglandins; Small molecules
- Mechanism of Action Platelet aggregation inhibitors; Prostaglandin D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 06 Dec 2000 Profile reviewed but no significant changes made
- 23 Sep 1998 No-Development-Reported for Thrombosis in United Kingdom (Unknown route)
- 21 Aug 1996 New profile